Skip to content
Take Aurally Therapeutics: Asthma episode artwork

Jan 5, 2018 20 min

Take Aurally Therapeutics: Asthma

from Take Aurally Hosted by Take Aurally

ED Pharmacist Kunal Gohil once again joins us in the Take Aurally booth in DREEAM to discuss the treatment of Asthma based on latest BTS guidelines. More information can be found at www.takeaurally.com. We can also be found on both Facebook and Twitter. NUH DREEAM can be found on both Facebook and Twitter.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Take Aurally Therapeutics: Asthma

0:00 20:02
of matches

Transcript Auto-generated, may contain errors

Thanks for downloading and welcome to Take Aurelie, the emergency medicine podcast recorded at Dream Queen's Medical Centre at Nottingham. In this episode we'll be discussing treatment of asthma. As everyone's information is correct at the time of recording, all guidelines mentioned are correct for Nottingham University Hospital's NHS Trust. Other trust guidelines may vary. All views and opinions are the speaker's own. Hello, welcome back to Take Aurelie. Jamie Thomas here, teacher fellow of emergency medicine, once again joined by Canal Ginhill. Hello, Dr. Thomas. Hello, Canal. How are you? Very well, very well. ED pharmacist extraordinaire. And in this episode we're going to be talking about the treatment of asthma. Sure.

Once again, there is a previous Take Orly podcast on asthma, myself and Charlie Peel, which mentions the diagnosis of asthma and looks very much at the acute management of asthma. Don Pennell was also in that podcast as well. So yeah, so for looking at the treatments of a patient coming in with acute exacerbation of asthma, please go to that podcast. In this podcast, again, much like with the COPD and Hypertension podcast, we're looking at the initiating treatments in the primary setting. That's right, yeah. Important because there's been some recent changes, I think, with the asthma guidelines, so it's nothing massively changing.

Important to note the changes, I think. We're at a cutting edge here. Yes, indeed. There's going to be a lot of cross-coverage here with COPD. We're going to be mentioning some very similar drugs. So we're not going to necessarily go in-depth about the mechanism of those drugs. Please refer back to the COPD podcast. Absolutely. So what is our first stage of treatment for our patient? So the key thing is, you're looking to protect your patient as best as you can at this point. So asthma, as we both know, because we've both been in ED for a while.

is a life-threatening condition and can kill somebody quite easily if it's not controlled properly. Absolutely, very quickly. So the key intervention, which is getting access to reliever therapy, in this case, like we spoke with COPD, salbutamol is usually our agent preferred. You can think about using it in protropium, as we spoke about again in the COPD podcast, but we found salbutamol tends to be a preferred option. In children, we'd be using it, potentially you can use up to 10 puffs of this for acute exacerbations.

And it's, again, that risk benefit of making sure we open the lungs up versus the side effects. We talked about tachycardia and things like that. But the key thing is to get them access to this reliever therapy so they can use it when they're getting potentially an asthma attack or identifying situations where they might develop that and to preemptively take this kind of therapy. short-acting meter agonist, so salbutamol. We said before terbutaline is the other option, which is if your patient prefers to try powder type inhaler. Remember as well, a spacer. I personally recommend anybody you're giving a new salbutamol inhaler to, we should be giving it with a spacer, because you're going to get so much more of the drug into the lung to do its work.

with a spacer rather than with the inhaler. The spacer slows it down. Absolutely, yeah. So you have to think that, you've got to think that, obviously, the mechanism of it, we're getting that constriction in the vessels. So in inhaled therapy, you need to get as much in as possible. If you're not getting enough in, you're not getting enough drug absorbed. So the spacer is really, really important, I think, whether it be for children or whether it be for adults.

Okay, as well as at that time, I suppose, lifestyle intervention, so you should not be smoking if you have asthma. You should be smoking anyway, but asthma, don't smoke. Getting your vaccinations, considering other things, is there a cat at home, and things like that. Absolutely. Doing what you can do. Yep, the immunizations and preventing the exposure of allergens. So asthma patients, over time, once they're diagnosed, they will have triggers, usually. The triggers can be as simple as going outside into the cold and taking a short breath. That can sometimes trigger an asthma attack. But as you say, cats, pets...

Sometimes particular perfumes and things like that can trigger it. So we should be counselling at this point to avoid these kind of triggers, to identify and avoid these kind of triggers. Even some food groups are associated with potentially making asthma worse in some patients, so more allergenic-y type foods. And that's something that will come along as the patient has their asthma. Absolutely, yeah. Okay, so that's very much looking at your short-term...

You've gone out without a breath, breathless, here's your ventral intake back. What if your patient's finding that they're needing to use that more often? That's right, yeah. What can we move on to then? So this is the interesting thing with the new guidance that's just come out, is now the guidelines are recommending a much earlier introduction of an inhaled corticosteroid. So steroids are very effective in asthma. We talked about using steroids further down the line in COPD, because their benefit is not as well understood. Asthma is an inflammatory, acinophilic-mediated...

So, anti-inflammatory effect from steroids is a lot more well understood, and it's got a benefit. So, currently, from the new guidances, we're... I should say, we're using our guidance here for NUH, but we've also got the British Thoracic Society guidance as well from September 2016 in front of us as well, I should say that now. That's right. So, once we've got the diagnosis of asthma, it now recommends initiating a low-dose inhaled corticosteroid straightaway now. That's the change from the previous guidelines, which was sort of use a short-acting visa, and then if you're getting exacerbations, then move up to the steroid. We're now starting steroids a lot earlier on.

Various different steroids. So in this case, at this step, you'd be starting an inhaled corticosteroid on its own, so a monotherapy inhaler. Here at Nottingham, we use Clenil as our first line, but there are various other ones. Pulbacol, Udesonide is an option. There's also Flitifazone, Flixotide, which is another option. We currently use Clenil here, mainly because of the cost thing, and it's just as effective as anything else. Usually 100 microgram inhaler, but you can use a 50 in children, and that would be one path twice a day, potentially going up to two paths twice a day. As we said before in the COPD podcast,

steroids in the mouth can potentially cause oral thrush. So it's about counselling the patient to rinse the mouth out and that sort of thing. Also again, like I said, for the salbutamol, if you prescribe it with a spacer, you're going to get a lot more of that drug into the lung. So we always recommend taking it with a spacer wherever possible. An interesting counselling point, which is a classic sort of pharmacist intervention, but it's a good thing for you to do initially, is potentially you've got your asthma patient who has two inhalers, blue and brown. Make sure they know which one's which. It sounds obvious, but there's lots of people that will use their brown inhaler whenever they want as a believer and say it's not working.

So make sure they know the blue one is for immediate exacerbations, and the brown one is the preventer. So make sure they've got that in their head. Because the salbutamol is bronchodilatory, it can actually improve deposition of steroid in the lung. So what I mean by that is if you're starting a patient on both, what we should be counselling them to do is before taking their dose of steroid inhaler, their Clenid, for example, they should have a dose of salbutamol immediately before, even if they don't have any symptoms at that point. What that does is it opens up the lung vasculature, and when you take the steroid inhaler, you're going to get better deposition into the lung. So it's a nice intervention to just improve the amount of steroid you can get available into the lung. Inhalcortical steroids, right at the beginning,

The patient's been taking those, still finding them that they're getting symptomatic very often over the week, not getting much relief, maybe waking up at night, short of breath. Where do we go to there? So at that point, we're going to think about, very similar to COPD, is getting them on a longer-term reliever. So the steroid is there doing its work as a preventer, but they're still getting the exacerbation, so we're needing to get them something potentially to stop the breathlessness. So at this point, we're always adding a labber in, so a long-acting beta-2 agonist.

At this point, adding the LABA and then being on a steroid, we would usually combine the inhaler rather than giving this poor patient three different inhalers to use. So they'll always have the SABA, the Ventolin or the Turbutylin. But at this point, you're changing their Clenil or their Flixotide to a combination product. Now, we'll talk about a couple of them which are commonly known. Ceratide, which is made by Glaxo. It's a monster of a drug.

And that's for ticasone with salmeterol. Sure. So it's in a twice daily preparation. It has that labyrinth, which, as we said in the COPD podcast, is going to sit nicely in the lung and do its continuous business of bronchodilating, whilst also giving you the steroid. So a good drug for that. That comes in an immediate dose inhaler, your standard puff type inhaler. So remember about the spaces still. If your patient doesn't like that type of inhaler, or you wanted to try something else for them, Simbacort is another option now. Now it comes in lots of different strengths. So it's starting the appropriate dose at that point, which is, I believe, the 106 dose we use, but I'll have to double check that.

That is a dry powder inhaler with Budesonide and Formortrol. So again, a similar combination. You've got the steroid doing its preventer business, and you've got the long-acting, sitting in the lung and doing that bronchodilation. The other option is Fossair, which is Beclomethazone and Formortrol. They're the three plastic inhalers that we use for Arsenal. But the key thing is one inhaler, which does both of that thing, helps the compliance for the patients. And as I said before, there's no reason still you can't counsel to use that salveutinol before using these combination inhalers to get better deposition into the lung. So it's all the way along, assessing inhaler technique, checking compliance, renewal.

Younger people may not necessarily be taking, but not necessarily be using properly. Yeah, absolutely. And like I'm already at this point, again, looking, keeping a diary maybe. Peak flows, so keeping a close eye on peak flows is a really good indicator of asthma control. So seeing how the peak flow is being affected after these interventions, so we've got an objective measure as well as a subjective measure in terms of how they're doing on a day-to-day basis. Okay. So what if our patient's still getting...

exacerbations, they're still getting admitted, they're still suffering, where can we go to from there? So we can still, we'd be going along the same lines, and at this point we'd be thinking about cranking that steroid dose up to give them a bit more power in the lung in terms of the anti-inflammatory effect. So that could be a case of increasing the strength of the serotide, the foster or the simbacore, so it's got more steroid in it pound for pound, or it could be changing the preparation altogether to a higher potency steroid. So if it's still inadequate, we're looking for sort of a medium dose of inhaled corticosteroid, so that varies depending on which particular steroid you're using. So potentially then, if that's still not working and the steroids are going up, we would start using our adjunct-type therapies, which are looking at the leukotriome receptor antagonist, which is Montelukast, which is not a bronchodonator per se, but it prevents some of that immune response in the lung and tries to dull that down, which is a potential addition to that.

You can think at this point about adding a Lameron. The evidence isn't as good. This works further down there than this, but in COPD we use it much earlier. In asthma we can use it later. So Spiriva is something we can use in asthma later on to see if there's potential benefit. There is still that effect on the small muscles that will get the bronchodilation for those patients. And then there's theophylline as well, which we talked about in COPD. We can think about using that in asthma for quite refractory cases with the same caveats that we discussed beforehand about smoking, about...

monitoring levels and keeping hypotoxicity. So we won't talk too much about them because there's some quite complex pharmacology going on, but that's why you're putting in the adjunct doses. I suppose at that point as well, if we've got a patient who's got quite stubborn asthma, they may have had hospital admissions, patients will start to have maybe their own asthma plan. I know especially we had a talk from a paediatric nurse, asthma specialist, who patients are now encouraged to have, you know, these are my haters, these are how often I use them. And in A&E we're seeing these patients that may have previously had an ICU admission.

a bit very unwell with their asthma. The patient's on a lot of different therapies as well. So we've added in potentially a leukotriene receptor antagonist. They may well be on theophylline. Is there a further step beyond that? I mean, at that point, you're really taking that steroid dose up to as high as you can physically tolerate. So we're talking very, very high doses of things like fliticozone. You can get up to one microgram per day, which is a lot of fliticozone. So really going up to the maximum amount of an inhaled steroid dose. At that point, then you're using

many of these adjuncts so maybe beforehand you've started them on tyotropium or theophyllin you're now putting them on tyotropium with theophyllin with a leukotriene receptor antagonist you're really throwing everything you can at that if you're still failing at that point and at this point when you're in step three or four you're looking to be potentially under a respiratory physician you're then looking at potentially oral steroids so maintenance steroids to stop that from happening And then you're looking at some monoclonal antibodies. Omolizumab, it's called, which is a very, very last-line brittle asthma treatment that's recommended by specialist respiratory teams. Very specialist. Yeah, that's not something that a GP is going to be starting, but that's sort of the last-line thing we're looking at at that point. Okay.

So a nice clear stepwise progression there and I think you know realising towards the end that's a multidisciplinary approach that your hospital team as well as community team you know as well as the patient themselves being well educated about their condition and again in A&E as we talked about in the Ascols podcast identifying these patients with brittle asthma at early doors even if they look well in front of you because as I'm sure you may have seen yourself I've certainly seen it they go from well to severely ill very quickly with asthma you know and so they need to be in recess they need ITU down and being aware of that that's right they can deteriorate so so quickly um and it really is a lot about educating them because um i think from my experience to be working in community before that was um that's one might sometimes have a tag of a common condition that you have that you know is something they take an inhaler for every so often yeah the fact of the matter is it's a very very dangerous life-breaking condition and somebody who's effectively symptomless for years, could very easily be exposed to a trigger or be in a situation where they've got a chest infection, where their asthma triggers, it can trigger quickly, and it could really become a life-threatening situation quickly. So that's educating patients, making sure, from a GP point of view, simple interventions like making sure they've got a spare inhaler for work, or a spare inhaler for the car, that sort of thing, which is actually a really important intervention. We potentially do a lot of emergency supplies of these inhalers. Yeah, it's certainly something I do in A&E. If my patient's saying, you know, I've used up my inhaler, it's been that kind of a week, and then actually they're all right, and then they are going home.

It's easy to think that it should seem obvious that if this patient has got a diagnosis of asthma and they need to have an inhaler, we should be giving them an inhaler. Equally, it is important to make sure that we're keeping an eye on that, so we don't want the situation where we're getting what is going to be effectively a poorly controlled asthmatic. just relying on Ventolin constantly and not having the other interventions made. So if you're seeing a patient that's using a lot of Ventolin and you're supplying lots and lots of inhalers for them... And they're only on the Ventolin. Absolutely. We should be reviewing that and thinking we need to put them on a chronic therapy to stop this from happening. If your patient comes in with an effective exacerbation of their asthma, you're starting antibiotic, is there a role for a short course of oral steroid as well? Yeah, I think the guidance says we can use a short course of steroids. It does depend on the level of severity that they've got. So you can potentially...

So obviously, infective exacerbation of asthma, by definition, is their asthma has gone worse, so they're problem saturating that sort of thing. Then we can think of that steroids. I think it's a 40 milligram a day short course. If they've got a standard chest infection where they're non-breathless or anything like that, it is equally reasonable to, say, just increase your inhaler use whilst you're taking these antibiotics. That's a clinical judgment to a certain extent. But you would have thought somebody that's attended A&E off their legs and really struggling, they will potentially need a short-term course. There is guidance about that, when to and when not to. And I suppose as well, the role of a GP or a physician is...

There's something we do here in NUH, the respiratory department over at City Hospital. If you're known to have a chronic lung condition, you carry the pink card. That's right. It's kind of your passport for coming in. So if they're too unwell, they come to A&E. But if you feel like you're struggling a bit, but you're not too unwell, they have that passport to go, I have a respiratory condition, ask for a COPD, bronchiectasis, whatever. And then they come in. That's something we can identify and educate about. Absolutely. It's so they can get the specialist care they need at the soonest time. They can see a pulmonologist. They can see a respiratory doctor much earlier on. They've got a very good idea about the history of these type of patients. So it's really important.

you know who you are and you tell the appropriate person about that card or history at that sort of point. And we listen to them. Absolutely. Brilliant. Thank you so much, Kunal. Fantastic. Bye-bye, everyone. That was the Take Orly Treating Asper podcast. As ever, you can find more information at www.takeorly.com, also on Facebook and Twitter. For more information on research and education opportunities within emergency medicine, acute medicine and major trauma, don't forget to check out NUH Dream on both Facebook and Twitter.

Frequently asked questions

How long is this episode of Take Aurally?

This episode is 20 minutes long.

When was this Take Aurally episode published?

This episode was published on January 5, 2018.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Take Aurally episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.